(RTTNews) - Clearmind Medicine Inc. (CMND), a clinical-stage biotech company developing psychedelic-derived treatments, has received Institutional Review Board or IRB approval from Tel Aviv Sourasky ...
Vancouver, Canada, July 03, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and ...
The Preston Robert Tisch Brain Tumor Center grants first IRB approval for APTN-101’s Phase I clinical trial, enabling patient recruitment to ...
Subject enrollment expected to begin in Q1 2026 CDI-988 is the first oral broad-spectrum antiviral drug candidate for potential prevention of norovirus outbreaks and treatment of acute viral ...
Company reaches next clinical trial milestone for the intramuscular treatment of Chronic Lower Back Pain with the first novel allogenic cellular therapy in the United States PHOENIX, Oct. 10, 2023 ...
-Study to Evaluate Usability and Extended Wear for Next-Generation Tubeless Patch Pump SAN DIEGO, CA / ACCESS Newswire / September 15, 2025 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or ...
The Purdue University Human Subject Protection Program is undergoing an internal assessment to ensure compliance with the institution's Federalwide Assurance. Researchers who have studies where IRB ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results